Athenex Inc banner
A

Athenex Inc
F:2MT

Watchlist Manager
Athenex Inc
F:2MT
Watchlist
Price: 0.12 EUR Market Closed
Market Cap: €715.7m

Athenex Inc
Total Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Athenex Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
A
Athenex Inc
F:2MT
Total Liabilities
$210.6m
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.2B
CAGR 3-Years
4%
CAGR 5-Years
0%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.3B
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
1%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$81.9B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
7%
Exact Sciences Corp
NASDAQ:EXAS
Total Liabilities
$3.5B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
57%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$7B
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
16%
No Stocks Found

Athenex Inc
Glance View

Market Cap
715.7m EUR
Industry
Biotechnology

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.

2MT Intrinsic Value
Not Available
A

See Also

What is Athenex Inc's Total Liabilities?
Total Liabilities
210.6m USD

Based on the financial report for Dec 31, 2022, Athenex Inc's Total Liabilities amounts to 210.6m USD.

What is Athenex Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
33%

Over the last year, the Total Liabilities growth was -3%. The average annual Total Liabilities growth rates for Athenex Inc have been 20% over the past three years , 33% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett